- Home
- SGC vs ITOS Comparison
SGC vs ITOS Comparison
Compare SGC & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- ITOS
- Stock Information
- Founded
- SGC 1920
- ITOS 2011
- Country
- SGC United States
- ITOS United States
- Employees
- SGC N/A
- ITOS N/A
- Industry
- SGC Apparel
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGC Consumer Discretionary
- ITOS Health Care
- Exchange
- SGC Nasdaq
- ITOS Nasdaq
- Market Cap
- SGC 281.4M
- ITOS 270.7M
- IPO Year
- SGC N/A
- ITOS 2020
- Fundamental
- Price
- SGC $10.80
- ITOS $6.88
- Analyst Decision
- SGC Strong Buy
- ITOS Strong Buy
- Analyst Count
- SGC 2
- ITOS 3
- Target Price
- SGC $19.00
- ITOS $26.00
- AVG Volume (30 Days)
- SGC 59.9K
- ITOS 384.6K
- Earning Date
- SGC 03-11-2025
- ITOS 03-05-2025
- Dividend Yield
- SGC 5.09%
- ITOS N/A
- EPS Growth
- SGC 35.19
- ITOS N/A
- EPS
- SGC 0.73
- ITOS N/A
- Revenue
- SGC $565,676,000.00
- ITOS $35,000,000.00
- Revenue This Year
- SGC $5.04
- ITOS N/A
- Revenue Next Year
- SGC $5.54
- ITOS $121.70
- P/E Ratio
- SGC $15.08
- ITOS N/A
- Revenue Growth
- SGC 4.12
- ITOS 177.89
- 52 Week Low
- SGC $10.75
- ITOS $6.67
- 52 Week High
- SGC $21.80
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- SGC 21.95
- ITOS 42.01
- Support Level
- SGC $10.74
- ITOS $6.73
- Resistance Level
- SGC $11.76
- ITOS $7.65
- Average True Range (ATR)
- SGC 0.55
- ITOS 0.36
- MACD
- SGC -0.20
- ITOS -0.01
- Stochastic Oscillator
- SGC 5.18
- ITOS 21.43
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.